MX2018005940A - Bloqueador del canal de sodio. - Google Patents
Bloqueador del canal de sodio.Info
- Publication number
- MX2018005940A MX2018005940A MX2018005940A MX2018005940A MX2018005940A MX 2018005940 A MX2018005940 A MX 2018005940A MX 2018005940 A MX2018005940 A MX 2018005940A MX 2018005940 A MX2018005940 A MX 2018005940A MX 2018005940 A MX2018005940 A MX 2018005940A
- Authority
- MX
- Mexico
- Prior art keywords
- sodium channel
- channel blocker
- present
- prevention
- pharmaceutically acceptable
- Prior art date
Links
- 239000003195 sodium channel blocking agent Substances 0.000 title abstract 2
- 229940125794 sodium channel blocker Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un compuesto representado por la Fórmula Química, o una sal farmacéuticamente aceptable del mismo. El compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades relacionadas con bloqueantes de canales de sodio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150159637 | 2015-11-13 | ||
| PCT/KR2016/013029 WO2017082688A1 (ko) | 2015-11-13 | 2016-11-11 | 소디움 채널 차단제 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005940A true MX2018005940A (es) | 2018-08-14 |
| MX376469B MX376469B (es) | 2025-03-07 |
Family
ID=58695815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005940A MX376469B (es) | 2015-11-13 | 2016-11-11 | Bloqueador del canal de sodio. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10227338B2 (es) |
| EP (1) | EP3375782B1 (es) |
| JP (1) | JP6559894B2 (es) |
| KR (1) | KR102245930B1 (es) |
| CN (1) | CN108349963B (es) |
| AU (1) | AU2016351526B2 (es) |
| BR (1) | BR112018009754B1 (es) |
| CA (1) | CA3003119C (es) |
| CL (1) | CL2018001281A1 (es) |
| CO (1) | CO2018005064A2 (es) |
| EC (1) | ECSP18038014A (es) |
| ES (1) | ES2821962T3 (es) |
| HR (1) | HRP20201695T1 (es) |
| HU (1) | HUE052569T2 (es) |
| MA (1) | MA43231B1 (es) |
| MX (1) | MX376469B (es) |
| MY (1) | MY194015A (es) |
| NZ (1) | NZ742069A (es) |
| PE (1) | PE20181301A1 (es) |
| PH (1) | PH12018500999A1 (es) |
| PL (1) | PL3375782T3 (es) |
| PT (1) | PT3375782T (es) |
| RS (1) | RS60927B1 (es) |
| RU (1) | RU2705578C1 (es) |
| SA (1) | SA518391540B1 (es) |
| SG (1) | SG11201803867TA (es) |
| SI (1) | SI3375782T1 (es) |
| TN (1) | TN2018000157A1 (es) |
| WO (1) | WO2017082688A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110072855A (zh) * | 2016-10-17 | 2019-07-30 | 基因泰克公司 | 治疗性化合物及其使用方法 |
| TW202003490A (zh) * | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2020052509A1 (zh) * | 2018-09-10 | 2020-03-19 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
| CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| KR100886854B1 (ko) * | 2001-03-12 | 2009-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | Ｎ-페닐아릴설폰아미드 화합물, 이 화합물을 유효성분으로서 함유하는 약제, 이 화합물의 합성 중간체 및이의 제조 방법 |
| JP2006290791A (ja) | 2005-04-11 | 2006-10-26 | Astellas Pharma Inc | アゾール置換スルホニルベンゼン誘導体 |
| US20090221581A1 (en) * | 2005-05-25 | 2009-09-03 | Philipp Wabnitz | Methods of treating pain |
| US7888345B2 (en) | 2006-06-09 | 2011-02-15 | Merck Sharp & Dohme Corp. | Benzaepinones as sodium channel blockers |
| EP2139852A1 (en) * | 2006-12-19 | 2010-01-06 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| JP2008290791A (ja) * | 2007-05-22 | 2008-12-04 | Funai Electric Co Ltd | 画像形成装置 |
| US8124610B2 (en) * | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
| CU24099B1 (es) * | 2009-01-12 | 2015-06-30 | Pfizer Ltd | Derivados de sulfonamida para el tratamiento del dolor |
| EP2593432B1 (en) * | 2010-07-12 | 2014-10-22 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
| CN104093716B (zh) * | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
| WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US9085517B2 (en) | 2011-12-15 | 2015-07-21 | Pfizer Limited | Sulfonamide derivatives |
| WO2013093688A1 (en) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Sulfonamide derivatives and use thereof as vgsc inhibitors |
| AR091112A1 (es) | 2012-05-22 | 2015-01-14 | Genentech Inc | Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7 |
| EP3444249B1 (en) * | 2012-10-15 | 2020-05-13 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| WO2015130957A1 (en) * | 2014-02-27 | 2015-09-03 | Zalicus Pharmaceuticals, Ltd. | Heterocyclic inhibitors of the sodium channel |
-
2016
- 2016-11-11 KR KR1020160150511A patent/KR102245930B1/ko active Active
- 2016-11-11 WO PCT/KR2016/013029 patent/WO2017082688A1/ko not_active Ceased
- 2016-11-11 HU HUE16864614A patent/HUE052569T2/hu unknown
- 2016-11-11 SG SG11201803867TA patent/SG11201803867TA/en unknown
- 2016-11-11 AU AU2016351526A patent/AU2016351526B2/en active Active
- 2016-11-11 CA CA3003119A patent/CA3003119C/en active Active
- 2016-11-11 MX MX2018005940A patent/MX376469B/es active IP Right Grant
- 2016-11-11 RS RS20201235A patent/RS60927B1/sr unknown
- 2016-11-11 JP JP2018524451A patent/JP6559894B2/ja active Active
- 2016-11-11 MA MA43231A patent/MA43231B1/fr unknown
- 2016-11-11 EP EP16864614.9A patent/EP3375782B1/en active Active
- 2016-11-11 PL PL16864614.9T patent/PL3375782T3/pl unknown
- 2016-11-11 BR BR112018009754-3A patent/BR112018009754B1/pt active IP Right Grant
- 2016-11-11 TN TNP/2018/000157A patent/TN2018000157A1/en unknown
- 2016-11-11 PE PE2018000765A patent/PE20181301A1/es unknown
- 2016-11-11 HR HRP20201695TT patent/HRP20201695T1/hr unknown
- 2016-11-11 ES ES16864614T patent/ES2821962T3/es active Active
- 2016-11-11 RU RU2018119954A patent/RU2705578C1/ru active
- 2016-11-11 MY MYPI2018000662A patent/MY194015A/en unknown
- 2016-11-11 US US15/771,775 patent/US10227338B2/en active Active
- 2016-11-11 CN CN201680066269.7A patent/CN108349963B/zh active Active
- 2016-11-11 SI SI201630902T patent/SI3375782T1/sl unknown
- 2016-11-11 NZ NZ742069A patent/NZ742069A/en unknown
- 2016-11-11 PT PT168646149T patent/PT3375782T/pt unknown
-
2018
- 2018-05-08 PH PH12018500999A patent/PH12018500999A1/en unknown
- 2018-05-09 SA SA518391540A patent/SA518391540B1/ar unknown
- 2018-05-10 CL CL2018001281A patent/CL2018001281A1/es unknown
- 2018-05-11 CO CONC2018/0005064A patent/CO2018005064A2/es unknown
- 2018-05-18 EC ECIEPI201838014A patent/ECSP18038014A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020014586A2 (es) | Compuestos | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CO2019004034A2 (es) | Compuesto de piridina | |
| MX2018009175A (es) | Agonista fxr derivado de esteroides. | |
| ES2721001T3 (es) | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| CL2013000713A1 (es) | Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial. | |
| DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
| MX2016011160A (es) | Tratamiento de afecciones asociadas con la hiperinsulinemia. | |
| CR20150325A (es) | Compuestos trcíclicos para inhibir el canal cftr | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| CO2018005064A2 (es) | Bloqueador del canal de sodio | |
| MX362919B (es) | Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1]. | |
| MX2019002369A (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial. | |
| ECSP18009366A (es) | Antagonistas del receptor de cgrp | |
| DOP2019000021A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| MX2017006110A (es) | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. | |
| AR110770A1 (es) | Moduladores del canal de potasio | |
| CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| CL2017002651A1 (es) | Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer | |
| MX2018007796A (es) | Compuestos de fenilimidazol. | |
| AR115865A2 (es) | Compuestos terapéuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: IN THERAPEUTICS |